|
|
|
|
| LEADER |
07601nmm a2200433 u 4500 |
| 001 |
EB000624613 |
| 003 |
EBX01000000000000000477695 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9781461524496
|
| 100 |
1 |
|
|a Stanley, M.A.
|e [editor]
|
| 245 |
0 |
0 |
|a Immunology of Human Papillomaviruses
|h Elektronische Ressource
|c edited by M.A. Stanley
|
| 250 |
|
|
|a 1st ed. 1994
|
| 260 |
|
|
|a New York, NY
|b Springer US
|c 1994, 1994
|
| 300 |
|
|
|a XI, 332 p
|b online resource
|
| 505 |
0 |
|
|a An Imunodominant Region in HPV16.L1 Identified by T Cell Responses in Patients with Cervical Dysplasias -- Immunological Aspects of Cervical Carcinoma -- Analysis of Tumour-Infiltrating Lymphocytes in Cervical Carcinoma -- Lymphocyt-Mediated Natural Cytotoxicity to HPV 16 Infected Cervical Keratinocytes -- Animal Models and Therapeutic Strategies -- Skin Test Reactivity to Papilloma Cells is Long Lasting in Domestic Rabbits after Regression of Cottontail Rabbit Papillomavirus Induced Papillomas -- Modulation of the DTH Response to HPV 16 E7 -- Fine Characterization of the HPV16 E7 49-57 Tumor Protective Cytotoxic T Cell Epitope “RAHYNIVTF” -- Vaccination of Cattle With L2 Protein Prevents BPV-4 Infection -- Immune Responses to HPV 16 E7 -- Use of Double aro Salmonella Mutants to Stably Express HPV 16 E7 Protein Epitopes Carried by HBV Core Antigen -- An Experimental Tetracycline and Vitamin A Therapy of HPV Infections of the Lower Female Genital Tract --
|
| 505 |
0 |
|
|a Genotyping of Human Papillomavirus (HPV) by Single-Strand Conformational Polymorphism (SSCP) -- Human Papillomavirus Infection in Women with Cervical Cancer but without Cytological Abnormalities in the Preceding Years -- HPV Infection and Carcinomas of the Larynx -- Perinatal Transmission and Persistence of the Cancer Associated Human Papillomaviruses -- HP-DNA on Colpocytological Smears from HIV Positive Females -- Humoral Responses to HPV -- Humoral Immune Response to Genital Human Papillomavirus Infections -- HPV 16 Antibodies in Cervical Cancer Patients and Healthy Control Women -- Prevalence of Antibodies Against Defined HPV Epitopes Among Incident Cases of Cervical Neoplasia: Current Status and Concepts -- Serological Response to HPV 16 Infection -- Detection of Antibodies to L1, L2, and E4 Gene Products of Human Papillomavirus Types 6, 11, and 16 among HPV Infected Patients and Controls --
|
| 505 |
0 |
|
|a IgG Antibodies to Human Papillomavirus Type 16 and Serum Retinol May Jointly Protect against Cervical Neoplasia -- Prognostic Significance of Antibodies to HPV-16 E7/E4 Proteins and Fragments of Cytokeratin 19 in Invasive Cervical Carcinoma -- Development of Serological Assays for Detection of Anti-HPV-16 E6 and E7 Antibodies -- Detection by ELISA Test of Antibodies to Human Papillomavirus (HPV) Type 16 E7 in Patients with Benign or Malignant Papillomas from Skin or Mucosa -- Seroreactivity to a L2-derived Synthetic Peptide Correlates with the Number of Surgery-Necessitating Recurrences in Patients with Laryngeal papillomatosis -- Comparison of pVConformational Epitopes Expressed by L1 Proteins in Mammalian (COS) and Insect (Sf9)Cells -- Detection of Class-Specific Antibodies to Baculovirus-Derived Human Papillomarvirus Type 16 (HPV-16) Capsid Proteins -- Cell Mediated Immunity to HPV -- Evolution of Class I HLA antigen Presenting Molecules --
|
| 505 |
0 |
|
|a Major Histocompatibility Complex (MHC) Expression and Antigen Presentation in Cervical Cancer -- Analysis of MHC Class I Expression in HPV 16 Positive Cervical Carcinomas, in Relation to c-myc Overexpression -- Immunogenetic Study of Women with HPV Related Cancer of the Uterine Cervix -- Recurrent Respiratory Papillomatosis (RRP): Enriched HLA DQw3 Phenotype and Decreased Class I MHC Expression -- HPV 16-Derived Synthetic Peptides with Ability to Upregulate MHC Class I Expression on RMA-S or T2 Cells as Detected by Enzyme Immunoassay -- Regulation of MHC Class I., Class II and ICAM-1 Expression by Cytokines and Retinoids in HPV-Harboring Keratinocyte Lines -- Murine Cytotoxic T Cell Responses to Human Papillomavirus E7 Protein -- Immune Response to Human Papillomavirus Type 16E6 Oncoprotein -- Human Cytotoxic T Cell Epitopes in HPV 11: Relationships Between Allele-Specific Motifs, HLA Binding and Stimulation In Vitro --
|
| 505 |
0 |
|
|a Retinoids and IFN-? Synergistically Decrease Tumor Cell-Induced Angiogenesis and Stimulate Lymphocyte Induced Angiogenesis -- Release of Soluble Tumor Necrosis Factor-? (TNF-?) Receptor by HPV-Associated Neoplastic Cells -- Contributors Index
|
| 505 |
0 |
|
|a HPV Gene Expression -- The Antibody Response Against p53 in Cancer Patients -- Enhanced Production of Wild-Type p53 Inhibits Growth and Differentiation of Normal Foreskin Epithelial Cells but Not Cell Lines Containing Human Papillomavirus DNA -- Detection of Human Papillomavirus, Epstein Barr Virus and Elevated or Mutant p53 Expression in Squamous Cell Carcinoma of the Head and Neck -- Elevated Levels of the p53 Tumour Suppressor Gene in the Basal Layer of Recurrent Laryngeal Papillomas -- Expression of the E6 and E7 Genes of Human Papillomaviruses in Tumours of Different Dignity -- Detection of HPV-16 E2 Protein in Cervical Keratinocytes -- Evaluation of the Hybrid Capture Assay for Determination of Human Papilloma Virus -- Utilization of a PCR-based, Multiple Restriction Endonuclease Digest Technique for Enhanced Detection and Typing of HPV from Clinical Samples -- A Gene Cassette for High Level Expression of the LI Capsid Protein of HPV-16 in Heterologous Cells --
|
| 653 |
|
|
|a Animal Anatomy
|
| 653 |
|
|
|a Microbial ecology
|
| 653 |
|
|
|a Anatomy, Comparative
|
| 653 |
|
|
|a Botany
|
| 653 |
|
|
|a Immunology
|
| 653 |
|
|
|a Microbial Ecology
|
| 653 |
|
|
|a Medical Microbiology
|
| 653 |
|
|
|a Plant Science
|
| 653 |
|
|
|a Medical microbiology
|
| 653 |
|
|
|a Pathology
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 028 |
5 |
0 |
|a 10.1007/978-1-4615-2449-6
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-1-4615-2449-6?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.079
|
| 082 |
0 |
|
|a 571.96
|
| 520 |
|
|
|a This volume represents a series of papers presented at the Second International Workshop on HPV Immunology held at the University of Cambridge July 5-7 1993. This Workshop and its predecessor held in Amsterdam in May 1992 were two of the major activities of the European Concerted Action "Immunology of Human Papillomavirus and Vaccine Development". The Concerted Action (CA) was supported by grants from the Commission of the European Communities (EC), the French Association for Cancer Research (ARC) and the European Association for Medical Research (EAMR). Twenty two laboratories throughout Europe and Scandinavia were members of the CA, the objectives of which were to develop collaborations, implement scientific exchanges and co-operate in a collective effort to develop vaccination strategies for HPV. HPV's are ubiquitous pathogens and evidence which has been accumulated over the past decade leaves little doubt that infection with certain HPV types (the so called "oncogenic HPV's" 16, 18 and their relatives) is the major risk factor in the development of cancer of the uterine cervix in women. Since an infectious agent, a virus, is implicated as the main aetiologic factor in this disease, the possibility is raised that if one could prevent HPV infection or treat established infections this would be an effective anti-cancer strategy against what is the commonest cancer in women worldwide
|